Steven Leonard Chapman Sells 4,728 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 4,728 shares of Natera stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the completion of the transaction, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. This represents a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $468,111.60.
• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total value of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total value of $645,483.52.

Natera Stock Performance

NASDAQ:NTRA traded down $5.05 during mid-day trading on Friday, reaching $146.06. 2,242,126 shares of the company's stock were exchanged, compared to its average volume of 1,338,689. The firm has a market capitalization of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. Natera, Inc. has a one year low of $52.01 and a one year high of $167.79. The business's fifty day simple moving average is $127.38 and its two-hundred day simple moving average is $115.46.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.95) EPS. Analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NTRA shares. BTIG Research lifted their target price on Natera from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Canaccord Genuity Group boosted their price target on Natera from $150.00 to $165.00 and gave the stock a "buy" rating in a research note on Wednesday. Robert W. Baird upped their target price on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Wednesday. StockNews.com downgraded Natera from a "hold" rating to a "sell" rating in a report on Thursday. Finally, Morgan Stanley upped their price objective on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $137.65.

Institutional Trading of Natera

Several institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company's stock worth $483,034,000 after purchasing an additional 532,874 shares during the last quarter. First Light Asset Management LLC grew its holdings in shares of Natera by 295.9% in the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company's stock worth $60,063,000 after purchasing an additional 490,822 shares during the last quarter. AQR Capital Management LLC lifted its stake in Natera by 257.6% in the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company's stock worth $70,553,000 after acquiring an additional 469,327 shares during the period. Finally, PointState Capital LP lifted its position in Natera by 112.0% during the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company's stock valued at $99,343,000 after buying an additional 413,468 shares during the period. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.